Combined intraarterial chemotherapy and radiotherapy in the treatment of Bladder carcinoma

Mokarim, Abul; Uetani, Masataka; Hayashi, Nobuyuki; Sakamoto, Ichiro; Minami, Kazunori; Ogawa, Yoji; Ochi, Makoto; Matsuoka, Yoshikazu; Hayashi, Kuniyaki; Nomata, Koichiro

doi:10.1002/(sici)1097-0142(19971101)80:9<1776::aid-cncr12>3.0.co;2-2

Cited by 53 publications

(27 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mokarin et al 44 published the results of an IA chemoradiotherapy trial for muscle-invasive bladder cancer. They treated 35 patients with IA CDDP and doxorubicin in combination with radiation; the CR rate was 74% and the survival rate was 76.6% at 5 years with a median followup interval of 45 months.…”

Section: Rtog 99-06mentioning

confidence: 99%

Chemoradiotherapy as a bladder-preservation approach for muscle-invasive bladder cancer: current status and perspectives

Sumiyoshi

2004

Int J Clin Oncol

View full text Add to dashboard Cite

Radical cystectomy has been considered the gold standard for the treatment of muscle-invasive bladder cancer. However, because of disappointing results with radical surgery in terms of survival and decreased quality of life (QOL), bladder-preservation treatment has been introduced as an alternative to radical cystectomy. The primary purpose of the bladder-preservation approach has been to maximize overall cure rates, with the secondary purpose being to preserve the patient's bladder. The modalities used to ensure successful bladder preservation include radical transurethral resection (TUR), concurrent cisplatin (CDDP)-based chemotherapy, and radiotherapy. In patients who achieve a complete response (CR) after trimodality therapy, 5-year survival rates of more than 50%, the same as those of radical cystectomy, can be achieved and 70% of this group will retain an intact functional bladder. In this article, bladder-preservation studies using chemoradiotherapy are reviewed.

show abstract

Section: Rtog 99-06mentioning

confidence: 99%

Chemoradiotherapy as a bladder-preservation approach for muscle-invasive bladder cancer: current status and perspectives

Sumiyoshi

2004

Int J Clin Oncol

View full text Add to dashboard Cite

show abstract

“…9 However, the long-term outcomes of this combined therapy have been unknown. Thus, in the present study, we report the long-term follow-up data from our conservative treatment of invasive bladder carcinoma, regardless of whether bladder preservation was possible.…”

Section: Introductionmentioning

confidence: 99%

Long‐term follow up of patients with invasive bladder carcinoma receiving combined cisplatin‐based intra‐arterial chemotherapy and radiotherapy

et al. 2007

Self Cite

View full text Add to dashboard Cite

Objectives: Combined cisplatin-based intra-arterial chemotherapy and radiotherapy is an effective treatment for patients with locally invasive bladder carcinoma. We report long-term follow-up data regarding definitive treatment of locally invasive bladder carcinoma, regardless of whether bladder preservation was possible. Methods: The follow-up data from 24 patients (18 males and six females; aged , 31-85 years; median, 73 years) with invasive bladder carcinoma, between 1993 and 2003, was examined. The clinical stages of the patients ranged T2-T4, all N0M0, and involved 13 patients at T2 (T2a, T2b), seven patients at T3 and four patients at T4. Combined cisplatin-based intra-arterial chemotherapy and radiotherapy was performed. Results:The 5-year overall survival rate and cancer-specific survival rate for all patients were 81.6% and 85.6%, respectively. When the patients were divided into complete response (CR) of 10 patients and non-CR groups of 14 patients, the 5-year overall survival rate for the CR group was 87.5%, while that of the non-CR group was 78.6% (P = 0.58). The tumor grade of the CR group was significantly lower than that of the non-CR group (P = 0.01). When the non-CR group was divided into radical cystectomy and non-radical cystectomy groups, the 5-year overall survival rate for the radical cystectomy group (100%) was higher than that of the non-radical cystectomy group (70%). Conclusion: This combined chemo-radiotherapy was effective for local invasive bladder carcinoma, leading to the possibility of bladder preservation using this therapy.

show abstract

“…We chose a protocol excluding radiotherapy to avoid adhesion formation following radiation therapy for total cystectomy in the refractory case. However, the recent literature on bladder preservation therapy does not mention this side effect in radiation therapy [9][10][11][12][13]21,22]. Compared with the results of protocols that include radiotherapy, we consider that our results suggest the necessity of radiotherapy in bladder preservation therapy for high-risk T2--3N0M0 cases.…”

Section: Discussionmentioning

confidence: 64%

“…Intra-arterial chemotherapy, which can deliver a high concentration of the selected drug(s) to the target organ, is one method of bladder preservation therapy [9][10][11][12][13]. The response rate when treating the same type of tumour with intra-arterial cisplatin infusion was found to be 2--10 times that for intravenous administration [14,15].…”

Section: Introductionmentioning

confidence: 99%

Intra-arterial Combination Chemotherapy with Maximum Transurethral Resection of Bladder Tumour for T1 Grade 3 and T2--3N0M0 Bladder Cancers

Nemoto¹,

Tsuboi²,

Miura³

2011

J Cancer Sci Ther

View full text Add to dashboard Cite

Purpose: We evaluated the clinical outcomes following intra-arterial chemotherapy with maximum transurethral resection of bladder tumour (TURBT) for patients with T1 grade 3 (G3) and T2--3N0M0 bladder cancers. Material and methods:Patients were 27 males and 7 females with a median age of 63.6 years. With the cooperation of an interventional radiologist, cisplatin (100 mg/m 2 ), methotrexate (30 mg/m 2 ) and adriamycin (20 mg/ body) were administered via a catheter in 2 cycles every 4 weeks. Results:The 5-year cancer-specific survival rate in T1 G3, T2 and T3 was 100.0%, 57.3% and 50.0%, respectively. In T2--3N0M0 cases, complete response (CR) and non-CR were seen in 13 (46.4%) and 15 cases (53.6%), respectively. Response to treatment proved to be the most significant prognostic predictor of cancerspecific survival by multivariate analysis in T2--3N0M0 cases. T2--3N0M0 cases with ≥2 prognostic predictors at staging TURBT (age >70 years, male, size >3 cm and the presence of hydronephrosis) had an unfavourable outcome. There was a statistical association between the number of prognostic predictors at staging TURBT and response to treatment. Conclusion:These results suggest that our protocol prevents disease progression in T1 G3 cases, but that it is not suitable for T2--3N0M0 cases with ≥2 prognostic predictors at staging TURBT.

show abstract

Combined intraarterial chemotherapy and radiotherapy in the treatment of Bladder carcinoma

Cited by 53 publications

References 27 publications

Chemoradiotherapy as a bladder-preservation approach for muscle-invasive bladder cancer: current status and perspectives

Chemoradiotherapy as a bladder-preservation approach for muscle-invasive bladder cancer: current status and perspectives

Long‐term follow up of patients with invasive bladder carcinoma receiving combined cisplatin‐based intra‐arterial chemotherapy and radiotherapy

Intra-arterial Combination Chemotherapy with Maximum Transurethral Resection of Bladder Tumour for T1 Grade 3 and T2--3N0M0 Bladder Cancers

Contact Info

Product

Resources

About